Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Operating Expenses (2023 - 2024)

Kura Oncology (KURA) has disclosed Operating Expenses for 3 consecutive years, with $100.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 68.24% to $100.7 million in Q3 2025 year-over-year; TTM through Dec 2025 was $179.6 million, a 27.33% decrease, with the full-year FY2025 number at $371.1 million, up 50.2% from a year prior.
  • Operating Expenses was $100.7 million for Q3 2025 at Kura Oncology, up from $78.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.7 million in Q3 2025 to a low of $36.6 million in Q1 2023.
  • A 3-year average of $59.2 million and a median of $55.4 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 40.99% in 2024, then surged 68.24% in 2025.
  • Kura Oncology's Operating Expenses stood at $46.8 million in 2023, then skyrocketed by 63.25% to $76.3 million in 2024, then soared by 31.97% to $100.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Operating Expenses are $100.7 million (Q3 2025), $78.8 million (Q1 2025), and $76.3 million (Q4 2024).